MLYS

+ Watchlist + Portfolio

Mineralys Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.95
52-Week Range: $14.29 – $47.65
Market Cap: $2.28B
P/E (TTM): —
EPS (TTM): -4.20
Dividend Yield: —

Advanced Metrics

Price/Book: 3.33
PEG Ratio: —
Return on Equity: -80.88%
Return on Assets: -46.18%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 34.46
Debt/Equity: 0.18
Total Debt: $97.62M
Free Cash Flow: $-203.46M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.82B

MLYS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.25M	$70.36M	$168.58M	$132.01M
Selling, General & Admin	$5.23M	$14.30M	$23.82M	$38.59M
Operating Expenses	$31.48M	$84.66M	$192.40M	$170.60M
Operating Income	-$31.48M	-$84.66M	-$192.40M	-$170.60M
EBITDA	-$31.48M	-$84.66M	-$192.36M	-$170.54M
Pretax Income	-$29.80M	-$71.90M	-$177.81M	-$154.65M
Net Income	-$29.80M	-$71.90M	-$177.81M	-$154.65M
Diluted EPS	-0.76	-1.99	-3.66	-2.29
Diluted Shares	39.06M	36.19M	48.54M	67.66M

MLYS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$87.70M	$49.30M	$114.09M	$172.92M
Current Assets	$112.81M	$249.10M	$205.35M	$661.39M
Total Assets	$114.44M	$251.64M	$205.90M	$661.81M
Current Liabilities	$8.07M	$10.48M	$14.65M	$15.11M
Total Liabilities	$166.71M	$10.48M	$14.65M	$15.11M
Retained Earnings	-$52.81M	-$124.71M	-$302.52M	-$457.17M
Shareholders' Equity	-$52.27M	$241.15M	$191.26M	$646.69M
Working Capital	$104.74M	$238.62M	$190.71M	$646.27M

MLYS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.22M	-$81.17M	-$166.31M	-$142.42M
Capital Expenditure	—	—	-$96.00K	-$15.00K
Free Cash Flow	-$29.22M	-$81.17M	-$166.41M	-$142.43M
Depreciation & Amortisation	—	$0.00	$43.00K	$59.00K
Stock-Based Compensation	$455.00K	$5.06M	$11.34M	$19.32M
Investing Cash Flow	-$21.76M	-$160.47M	$114.96M	-$389.75M
Financing Cash Flow	$128.02M	$203.25M	$116.14M	$591.00M
Share Repurchases	-$1.63M	—	—	—
Net Change in Cash	$77.04M	-$38.40M	$64.79M	$58.83M

MLYS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$37.88M	$38.28M	$31.45M	$24.40M	$24.36M
Selling, General & Admin	$6.57M	$8.47M	$9.68M	$13.88M	$20.98M
Operating Expenses	$44.45M	$46.75M	$41.13M	$38.28M	$45.34M
Operating Income	-$44.45M	-$46.75M	-$41.13M	-$38.28M	-$45.34M
EBITDA	-$44.43M	-$46.73M	-$41.12M	-$38.27M	-$45.33M
Pretax Income	-$42.21M	-$43.27M	-$36.93M	-$32.23M	-$39.34M
Net Income	-$42.21M	-$43.27M	-$36.93M	-$32.23M	-$39.34M
Diluted EPS	-0.79	-0.66	-0.52	-0.40	-0.47
Diluted Shares	53.16M	65.45M	70.59M	80.55M	82.83M

MLYS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$165.01M	$101.79M	$217.60M	$172.92M	$112.78M
Current Assets	$354.51M	$335.27M	$599.80M	$661.39M	$652.47M
Total Assets	$354.94M	$335.72M	$599.95M	$661.81M	$652.86M
Current Liabilities	$13.39M	$22.17M	$23.52M	$15.11M	$14.72M
Total Liabilities	$13.39M	$22.17M	$23.52M	$15.11M	$14.72M
Retained Earnings	-$344.73M	-$388.00M	-$424.94M	-$457.17M	-$496.51M
Shareholders' Equity	$341.56M	$313.55M	$576.43M	$646.69M	$638.14M
Working Capital	$341.12M	$313.10M	$576.28M	$646.27M	$637.75M

MLYS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$45.49M	-$30.17M	-$28.87M	-$37.89M	-$39.47M
Free Cash Flow	-$45.49M	-$30.17M	-$28.87M	-$37.90M	-$39.47M
Depreciation & Amortisation	$15.00K	$16.00K	$15.00K	$13.00K	$6.00K
Stock-Based Compensation	$3.65M	$4.55M	$5.84M	$5.29M	$6.55M
Investing Cash Flow	-$92.88M	-$42.88M	-$150.51M	-$103.49M	-$44.94M
Financing Cash Flow	$189.28M	$9.83M	$295.19M	$96.70M	$24.27M
Net Change in Cash	$50.92M	-$63.22M	$115.81M	-$44.68M	-$60.14M

Market Snapshot

About

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and chronic kidney disease. The company's lead candidate, lorundrostat, is an aldosterone synthase inhibitor designed to lower blood pressure and reduce cardiovascular and renal risk. Mineralys targets patients with uncontrolled hypertension and cardiorenal conditions.